VitMode
Mikroskopowy obraz struktury komórek roślinnychturek / Pexels
Guides

Quercetin as a Senolytic: What the First Human Studies of the Dasatinib + Quercetin Combination Show

Quercetin, the same flavonoid we covered in an earlier article in the context of allergic rhinitis, plays an entirely different, far more experimental role in aging biology: as part of a combination with the oncology drug dasatinib (the "D+Q" protocol), studied as a senolytic — a substance that selectively clears senescent cells. This is the first pair of senolytic compounds for which real data have been published showing a reduction in senescent cells in humans, not just in animals. We take a close look at what these first clinical trials actually showed, what role quercetin itself actually plays in them, and where the limits of this evidence lie.

AKdr Anna KowalczykSeptember 9, 202613 min read
Table of contents

TL;DR — key takeaways

The same flavonoid, a completely different research context

In an earlier article on quercetin and allergic rhinitis, we described this flavonoid in the context of its potential antihistamine action, confirmed in one clinical trial in people with hay fever. This article covers a completely different, far more experimental application: quercetin as part of a senolytic combination, studied in the context of aging biology, not allergy. If you're looking for information about quercetin for hay fever, that earlier article is the right place — here we focus exclusively on its senolytic role.

Quercetin on its own shows moderate senolytic properties in laboratory studies, but in research practice it's rarely tested in this context on its own — most often it's combined with dasatinib, an oncology drug (a tyrosine kinase inhibitor) used to treat chronic myeloid leukemia. This combination, known in the literature as "D+Q" (dasatinib + quercetin), is today the best-studied pair of senolytic compounds in humans.

Why a combination, not quercetin alone

The hypothesis behind combining dasatinib and quercetin is that senescent cells avoid death through multiple, partly overlapping survival pathways (SCAPs). Dasatinib and quercetin target partly different ones of these pathways, so in theory their combination eliminates a broader range of senescent cells than either compound alone — but this also means that in most clinical trials it's not possible to fully separate quercetin's contribution from dasatinib's.

The first data showing a reduction in senescent cells in humans

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

Early-stage evidence

Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK et al. · EBioMedicine · 2019

An open-label, small pilot trial in people with diabetic kidney disease, given dasatinib and quercetin for three days. Eleven days after treatment ended, a reduction was observed in skin and fat-tissue cells bearing senescence markers (p16INK4A and p21CIP1), along with a decrease in circulating SASP factors (pro-inflammatory signals secreted by senescent cells, including IL-1α, IL-6, and the matrix metalloproteinases MMP-9 and MMP-12). This was one of the first studies to show that short-term administration of senolytics can reduce the number of senescent cells and associated inflammatory markers directly in humans, not just in animal models.

View study

Important context: a correction was issued

A formal corrigendum (correction) to this publication was issued in 2020, following a re-analysis of the raw data — some of the conclusions presented were revised relative to the original publication. This doesn't mean the study is worthless, but it's an important signal that the results of this first, small pilot trial should be treated with appropriate caution, not as a definitively confirmed fact.

A second pilot study — idiopathic pulmonary fibrosis

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

Early-stage evidence

Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK et al. · EBioMedicine · 2019

A two-site, open-label pilot trial in 14 people with idiopathic pulmonary fibrosis (IPF) — a disease strongly linked in animal-model studies to the accumulation of senescent cells. Participants took intermittent dasatinib (100 mg/day) and quercetin (1,250 mg/day) three days a week for three weeks. The main goal was to assess the feasibility and safety of the protocol, not clinical efficacy. Lung function did not change significantly over this short observation period. One serious adverse event was recorded (suspected bacterial, multifocal pneumonia with pulmonary edema against a background of IPF), requiring temporary hospitalization, with complete resolution of symptoms.

View study

The researchers concluded that the pilot confirmed the feasibility of such a trial and gave preliminary indications that senolytics may ease physical dysfunction associated with IPF, justifying larger, randomized trials — but this is a conclusion about the need for further research, not about confirmed efficacy.

What both pilots have in common, and what separates them from clinical proof

Early-stage evidence

Both studies (kidney, lung) share a small number of participants, a short observation period, and no placebo control group in the full sense of the term (the IPF trial was partly placebo-controlled in its pilot phase, but the main goal was assessing feasibility). This makes both studies important, first evidence that the D+Q protocol genuinely reduces senescence markers in humans — but not proof of a specific, hard clinical benefit (such as extended lifespan or slowed disease progression) over a longer period.

Personalized for you

Struggling with sleep?

Answer a few questions about your sleep, stress, diet, and lifestyle. VitMode will show you which areas might need the most attention and which supplements could be worth considering.

Takes about 2 minutesBased on scientific evidence
Check your profile

Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.

What is quercetin's actual role in these studies

Myth

The D+Q studies prove that quercetin is a strong, confirmed senolytic that can be used on its own with a similar effect.

Fact

None of the described studies tested quercetin alone, without dasatinib — so no conclusion about quercetin's standalone senolytic action in humans can be drawn from them. Data from animal and cellular models suggest that quercetin alone has moderate, weaker senolytic activity than dasatinib and targets a partly different set of cell-survival pathways, which is precisely the rationale for combining the two substances, not evidence that each alone produces a comparable effect.

This distinction has practical significance for anyone considering standalone quercetin supplementation while expecting the senolytic effect described in the context of D+Q studies — the available clinical data simply say nothing about this specific scenario, since it hasn't been tested in these trials.

Safety — dasatinib changes the risk balance

Dasatinib is an oncology drug with real side effects

Dasatinib is a registered drug used to treat chronic myeloid leukemia, with well-documented side effects including myelosuppression (reduced blood cell counts), fluid retention, pleural effusions, and, less commonly, pulmonary hypertension. The D+Q protocol studied in the context of senolysis uses this drug intermittently (e.g., three days a month rather than daily), which theoretically reduces exposure and risk relative to standard oncology treatment, but doesn't eliminate it — dasatinib remains a prescription drug requiring medical supervision, not a substance available for self-experimentation.

Quercetin alone, outside the D+Q context

Quercetin as an isolated supplement has a generally good safety profile at moderate doses, as we describe in more detail in our article on quercetin and allergic rhinitis, including its possible interactions with certain drugs via the liver enzyme CYP3A4. This safety profile, however, applies to quercetin used alone at typical supplemental doses — not to the D+Q protocol, which is a completely different, far more experimental intervention involving a prescription drug.

Frequently asked questions

There is no published clinical data on this — the available studies (kidney, lung) tested only the dasatinib+quercetin combination, not quercetin on its own. Data from animal and cellular models suggest that quercetin alone has weaker senolytic activity than in combination with dasatinib, but this hasn't been directly tested in clinical trials in humans.

It should not be used on your own without medical supervision — dasatinib is a prescription drug used standardly in oncology, with real side effects (myelosuppression, fluid retention). The protocols studied clinically in the context of senolysis are conducted under the supervision of research teams monitoring safety.

The earlier article covers quercetin used on its own in the context of allergic rhinitis, where one randomized clinical trial shows symptom improvement. This article covers a completely different application — quercetin as part of a senolytic combination with dasatinib, studied in the context of cellular aging, not allergy. These are two independent research contexts for the same substance.

No — this was a pilot study assessing primarily whether the D+Q protocol genuinely reduces markers of senescent cells in humans, not a clinical trial assessing the effect on kidney disease progression as a hard endpoint. In addition, a corrigendum was issued for the publication after a re-analysis of the data, which is a reason for additional caution when interpreting the results.

Researchers measured biochemical markers such as the proteins p16INK4A and p21CIP1 (indicators of cell-cycle arrest typical of senescence) and SASP factors — pro-inflammatory signals secreted by senescent cells, including interleukin-6 (IL-6) and matrix metalloproteinases (MMP-9, MMP-12). A reduction in these markers after D+Q treatment was the main result of both described pilot studies.

The idiopathic pulmonary fibrosis study showed no significant change in lung function over the short observation period, though researchers noted preliminary, promising signals regarding physical dysfunction that justify further, larger trials. Neither described study was designed to assess the effect on lifespan — such an endpoint would require a far longer observation period.

Current data don't support such a recommendation — the available clinical trials tested only the combination with dasatinib, a prescription drug with a different safety profile. Standalone quercetin supplementation hasn't been tested in this specific senolytic context in humans, so expecting an analogous effect has no scientific basis today.

Sources

AK

dr Anna Kowalczyk

PhD in Molecular Biology (University of Warsaw), 8 years researching cellular aging

Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.

Related articles

Świeże truskawki w ozdobnej misce

Fisetin as a Senolytic: What the Mouse Study Showed and Where Human Research Stands Today

Fisetin is a flavonoid found in strawberries, apples, and onions that made longevity-media headlines in 2018 as the strongest of the studied natural senolytics — compounds that selectively clear senescent (aging) cells. The mouse result was genuinely strong: extended lifespan and reduced markers of aging across many tissues. The problem is that several years have passed since that study, and clinical trials in humans are still at the stage of pilot safety trials, not confirmed efficacy. We take a close look at what is actually known and what remains only a promising hypothesis.

13 min

September 9, 2026

Naukowiec trzymający pipetę w niebieskich rękawiczkach w laboratorium

NMN vs NAD+ vs Resveratrol — What Actually Extends Life?

Three of the biggest names in longevity, one shared hypothesis, and a very different level of evidence in humans for each. An honest comparison of mechanism, clinical trial quality, and monthly cost — with no marketing rounding up.

14 min

August 20, 2026

Wygodne łóżko w sypialni oświetlone miękkim porannym słońcem

Vitamin D3 and Longevity — Does a Deficiency Shorten Your Life?

Low vitamin D levels correlate with higher mortality across dozens of observational studies, yet the massive randomized VITAL trial found no evidence that supplementation extends life in people without a deficiency. We break down this apparent contradiction piece by piece.

13 min

August 20, 2026

Kobieta śpiąca spokojnie w opasce na oczy w przyciemnionej sypialni

Sleep Biohacking — How Better Sleep Extends Your Life

Sleep tends to get treated as dead time, something to get through on the way to a productive morning. The epidemiological data says otherwise: both too little and too much sleep are linked to higher mortality risk, and sleep regularity turns out to matter more for survival than the raw number of hours. We gather what's actually known about sleep and longevity, and explain which sleep-biohacking habits actually have research behind them.

14 min

August 20, 2026

Related knowledge base entries

Zbliżenie na elegancki zegar symbolizujący upływ czasu4.3

Autophagy

An intracellular 'housekeeping' process that clears out damaged proteins and organelles, whose discovery earned a Nobel Prize — one of the key mechanisms studied in the context of slowing aging.

LongevityModerate evidence
Starsza osoba mierząca ciśnienie krwi cyfrowym aparatem w domu4.2

Immunosenescence

The progressive, multi-directional remodeling of the immune system with age — not a simple 'weakening,' but a complex change that both lowers the ability to fight new threats and raises the baseline level of inflammation.

LongevityModerate evidence
Kolorowa, abstrakcyjna reprezentacja nici DNA symbolizująca naukę i genetykę4.4

Telomeres and Telomerase

Protective 'caps' on the ends of chromosomes that shorten with every cell division — one of the most recognizable, though still imperfect, biomarkers of cellular aging.

LongevityModerate evidence
Kolorowa, abstrakcyjna reprezentacja nici DNA4.2

TFEB

The transcription factor TFEB acts as a master on-off switch for autophagy and the production of new lysosomes in the cell — one of the best-characterized molecular nodes linking these two processes, studied as a potential target for interventions in aging.

LongevityModerate evidence
Kolorowy model molekularny ilustrujący pojęcia naukowe4.1

Proteostasis

A cell's ability to maintain balance between protein production, correct folding, and degradation — a network of mechanisms whose capacity declines with age and is studied as one of the fundamental pillars of cellular aging.

LongevityModerate evidence
Dwoje naukowców prowadzących badania mikroskopowe w laboratorium3.9

Lysosomal Health

Lysosomes — the cell's 'recycling centers' — accumulate unprocessed waste and lose capacity with age, a pattern increasingly described as one of the fundamental, shared denominators of cellular aging and a potential target for future interventions.

LongevityEarly-stage evidence

Comments (2)

  • KW

    Kasia W. 2 weeks ago

    Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.

  • MT

    Marek T. a month ago

    Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.